David Lawrence Sells 31,000 Shares of Acorda Therapeutics Inc (ACOR) Stock

Acorda Therapeutics Inc (NASDAQ:ACOR) insider David Lawrence sold 31,000 shares of Acorda Therapeutics stock in a transaction dated Friday, January 19th. The stock was sold at an average price of $27.58, for a total transaction of $854,980.00. Following the completion of the transaction, the insider now directly owns 5,275 shares of the company’s stock, valued at $145,484.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Shares of Acorda Therapeutics Inc (NASDAQ ACOR) traded up $0.65 during midday trading on Wednesday, reaching $25.60. 726,713 shares of the company traded hands, compared to its average volume of 798,829. The company has a debt-to-equity ratio of 0.49, a current ratio of 2.77 and a quick ratio of 2.40. The company has a market capitalization of $1,156.99, a price-to-earnings ratio of -20.62 and a beta of 1.63. Acorda Therapeutics Inc has a 12 month low of $13.60 and a 12 month high of $33.00.

ACOR has been the subject of several recent analyst reports. HC Wainwright initiated coverage on shares of Acorda Therapeutics in a report on Wednesday, November 8th. They issued a “buy” rating and a $35.00 target price for the company. Cowen reaffirmed a “buy” rating and issued a $30.00 target price on shares of Acorda Therapeutics in a report on Friday, November 17th. TheStreet cut shares of Acorda Therapeutics from a “c-” rating to a “d+” rating in a report on Friday, November 17th. Zacks Investment Research raised shares of Acorda Therapeutics from a “strong sell” rating to a “hold” rating in a report on Wednesday, October 18th. Finally, Jefferies Group boosted their price objective on shares of Acorda Therapeutics from $22.00 to $25.00 and gave the company a “hold” rating in a report on Wednesday, November 1st. Three investment analysts have rated the stock with a sell rating, eleven have assigned a hold rating, two have issued a buy rating and one has given a strong buy rating to the company. The stock currently has an average rating of “Hold” and a consensus price target of $21.35.

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Teachers Advisors LLC grew its position in Acorda Therapeutics by 12.9% during the fourth quarter. Teachers Advisors LLC now owns 88,694 shares of the biopharmaceutical company’s stock valued at $1,902,000 after buying an additional 10,106 shares during the period. Alliancebernstein L.P. boosted its position in shares of Acorda Therapeutics by 40.8% in the fourth quarter. Alliancebernstein L.P. now owns 100,860 shares of the biopharmaceutical company’s stock worth $2,163,000 after purchasing an additional 29,230 shares during the period. Bogle Investment Management L P DE bought a new position in shares of Acorda Therapeutics in the fourth quarter worth approximately $5,350,000. Sphera Funds Management LTD. bought a new position in shares of Acorda Therapeutics in the fourth quarter worth approximately $1,073,000. Finally, Virtus Fund Advisers LLC bought a new position in shares of Acorda Therapeutics in the fourth quarter worth approximately $991,000.

COPYRIGHT VIOLATION WARNING: This piece of content was posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece of content on another website, it was illegally stolen and republished in violation of United States and international trademark and copyright laws. The legal version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/02/14/acorda-therapeutics-inc-acor-insider-david-lawrence-sells-31000-shares-of-stock.html.

Acorda Therapeutics Company Profile

Acorda Therapeutics, Inc is a biopharmaceutical company. The Company focuses on developing therapies that restore function and improve the lives of people with neurological disorders. As of December 31, 2016, the Company marketed three United States Food and Drug Administration (FDA)-approved therapies, including Ampyra (dalfampridine) Extended Release Tablets, 10 milligram (mg), a treatment to improve walking in patients with multiple sclerosis (MS).

Insider Buying and Selling by Quarter for Acorda Therapeutics (NASDAQ:ACOR)

Receive News & Ratings for Acorda Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acorda Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply